02:02:18 EDT Sat 19 Jul 2025
Enter Symbol
or Name
USA
CA



Avricore Health Inc
Symbol AVCR
Shares Issued 101,289,664
Close 2025-07-10 C$ 0.075
Market Cap C$ 7,596,725
Recent Sedar Documents

Avricore expands HealthTab to north-central London

2025-07-10 16:38 ET - News Release

Mr. Rodger Seccombe reports

AVRICORE HEALTH'S HEALTHTAB™ PLATFORM EXPANDS TO NORTH CENTRAL LONDON IN GROUNDBREAKING NHS PHARMACY-LED CARDIOVASCULAR PROJECT

Avricore Health Inc. has expanded its HealthTab platform into pharmacies in north-central London -- making it the second NHS Integrated Care Board (ICB), after northeast London, to join this groundbreaking initiative aimed at tackling health inequalities through cholesterol screening. Six new HealthTab systems were deployed in this phase, expanding the United Kingdom network to 13 participating pharmacies.

The north-central London expansion will bring HealthTab to even more patients, with a continued focus on underserved populations and reducing health disparities. By expanding access to preventative testing, the program supports the U.K.'s broader vision for a more agile and accessible health care system.

"This initiative is fundamentally changing how healthcare is delivered," said Rodger Seccombe, chief executive officer of Avricore Health. "By empowering pharmacists to take a leading role in chronic disease prevention and patient care, we're making health care more effective, more accessible and more responsive to the needs of both patients and providers."

This next phase also represents significant momentum in the U.K.'s efforts to transform community pharmacies into accessible hubs for chronic disease prevention and management.

"Building on the success of our work in northeast London, we're proud to see this innovative model expand into our neighbouring ICB. By integrating specialist cardiovascular expertise into neighbourhood health teams and community pharmacies, we are enabling earlier detection, timely intervention and more equitable care. This is a critical step in transforming how we prevent and manage cardiovascular disease -- bringing prevention closer to people's homes and embedding specialist support where it can have the greatest impact," said Prof. Riyaz Patel, clinical lead for prevention, Barts Health NHS Trust and professor of cardiovascular prevention at University College London.

Project partners leading innovation in pharmacy care

The initiative is being delivered as part of the East London Prevention Strategy in collaboration with a group of visionary health care organizations: Barts Health NHS Trust, NHS North Central London, NHS North East London, North East London Local Pharmaceutical Committee, UCLPartners and Heart U.K. (Barts/UCL initiative). This multidisciplinary approach unites providers, pharmacists and health system leaders in a shared mission: improve cardiovascular outcomes through earlier detection and better access to clinical services at the pharmacy level.

U.K.'s global leadership in pharmacy-based clinical services

The NHS Pharmacy First program, recent cardiovascular disease (CVD) screening initiatives and the use of digital health tools like the NHS app demonstrate the U.K.'s commitment to a decentralized, patient-centric model of care. By reimagining the role of pharmacists with clear mandates, timelines and funding, the U.K. is demonstrating that health care can meet the challenges of the day by better utilizing existing resources.

In September, 2026, a critical milestone of the NHS Community Pharmacy Independent Prescribing Pathfinder Programme will take effect, granting community pharmacists the authority to diagnose and prescribe for chronic conditions such as diabetes and cardiovascular disease. Pharmacy teams have already successfully integrated blood pressure screening and, with the support of HealthTab, are now expanding their capabilities to include point-of-care testing. In the lead-up to this milestone, the HealthTab and Barts/UCL initiative is expected to expand to additional integrated care boards (ICBs), providing pharmacists with the tools, data and clinical infrastructure needed to fully leverage their prescribing authority and deliver more pro-active, patient-centred care.

Tackling chronic disease at the front lines of care

CVD remains the leading cause of death in the U.K., and prevention is a national priority. Early intervention -- especially in underserved communities -- is critical to reducing health inequalities and long-term health care costs.

Initial NHS investments in pharmacy-based screening programs have demonstrated strong uptake and clear value for both patients and providers. In a report released on Oct. 11, 2024, the NHS Confederation -- which represents over 1.5 million health care staff, cares for more than one million patients daily, and oversees 150 billion pounds sterling in public spending -- highlighted community-based CVD screening and prevention as among the highest-return health care investments. The report cited returns of 7.52 pounds sterling for every one pound sterling spent on cardiovascular screening and nine pounds sterling for diabetes after five years, noting that "implementing community pharmacies to aid in the detection of CVD provided the quickest return, within one year."

Seamless data integration and patient engagement

Building a truly innovative and effective service means collaboration amongst technology providers. In January of this year, a partnership and successful integration between HealthTab and Patient Knows Best (PKB) enabled real-time pharmacy test results to be integrated into patients' personal NHS health records, enhancing access for both patients and providers.

Integrating HealthTab results with PKB accounts, already serving 4.8 million users, aims to seamlessly incorporate patient test outcomes into their personal health records within the NHS. On the back of the results, the pharmacy software provides the patient with a care plan stored in their PKB record for easy reference, supporting behaviour change. This integration fosters interoperability between health professionals to enable better collaboration, improved clarity in patient care and more effective use of critical health data.

About HealthTab

HealthTab is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and reports data in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (that is, HbA1c, Lipid Profile, eGFR). HealthTab has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing and consumables, direct access testing, disease prevention and management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third party app integration through API (application programming interface).

About Avricore Health Inc.

Avricore Health is a pharmacy service innovator focused on acquiring and developing early stage technologies aimed at advancing pharmacy practice and patient care. Through its flagship offering HealthTab, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

We seek Safe Harbor.

© 2025 Canjex Publishing Ltd. All rights reserved.